Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability

Neurobiology of Disease

Volumn 32, Issue 3, 2008, Pages 521-527

  Pieper, Heike C ^a   Evert, Bernd O ^a   Kaut, Oliver ^a   Riederer, Peter F ^b   Waha, Andreas ^a   Wüllner, Ullrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Excellence Research Laboratories   (Germany)

Author keywords

DNA methylation; Epigenetics; Neuroinflammation; Parkinson's disease; Promoter studies; Substantia nigra

Indexed keywords

TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALZHEIMER DISEASE; ARTICLE; BINDING SITE; BRAIN CORTEX; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DEGENERATIVE DISEASE; DNA METHYLATION; DOPAMINERGIC NERVE CELL; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; BASE SEQUENCE; CELLS, CULTURED; CEREBRAL CORTEX; DINUCLEOSIDE PHOSPHATES; DNA METHYLATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; SUBSTANTIA NIGRA; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 56449115830     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2008.09.010     Document Type: Article

References (29)

1. Bird A.P., and Wolffe A. Methylation-induced repression - belts, braces, and chromatin. Cell 99 (1999) 451-454
2. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., and Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172 (1994) 151-154
3. Carvey P.M., Chen E., Lipton J.W., Tong C.W., Chang Q.A., and Ling Z.D. Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat. J. Neural. Transm. 112 (2005) 601-612
4. Cedar H. DNA methylation and gene activity. Cell 8 (1988) 3-4
5. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., and Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 58 (2005) 963-967
6. Comb M., and Goodman H. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res. 18 (1990) 3975-3982
7. Clark S.J., Harrison J., and Molloy P.L. Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene 195 (1997) 67-71
8. Economou J.S., Rhoades K., Essner R., McBride W.H., Gasson J.C., and Morton D.L. Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line. J. Exp. Med. 170 (1989) 321-326
9. Evert B.O., Araujo J., Vieira-Saecker A.M., de Vos R.A., Harendza S., Klockgether T., and Wüllner U. Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J. Neurosci. 26 44 (2006) 11474-11486
10. Ferger B., Leng A., Mura A., Hengerer B., and Feldon J. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem. 89 (2004) 822-833
11. Krüger R., Hardt C., Tschentscher F., Jäckel S., Kuhn W., Müller T., Werner J., Woitalla D., Berg D., Kühnl N., et al. Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. J. Neural. Transm. 107 (2000) 553-562
12. McGeer P.l., and McGeer E. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 21 (1995) 195-218
13. McGeer P.L., Yasojima K., and McGeer E.G. Inflammation in Parkinson's disease. Adv. Neurol. 86 (2001) 83-89
14. Mirza B., Hadberg H., Thomsen P., and Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95 (2000) 425-432
15. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., and Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 3 (1994) 208-210
16. Muiznieks I., and Doerfler W. The impact of 5′-CG-3′methylation on the activity of different eukaryotic promoters: a comparative study. FEBS Lett. 16 (1994) 251-254
17. Nagatsu T., Mogi M., Ichinose H., and Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural. Transm. Suppl. 60 (2000) 277-290
18. Nishimura M., Mizuta I., Mizuta E., Yamasaki S., Ohta M., Kaji R., and Kuno S. Tumor necrosis factor gene polymorphisms in patients with sporadic Pakinson's disease. Neurosci. Lett. 21 (2001) 1-4
19. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 14 (2003) 185-191
20. Siegmund K.D., Connor C.M., Campan M., Long T.I., Weisenberger D.J., Biniszkiewicz D., Jaenisch R., Laird P.W., and Akbarian S. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS ONE 2 9 (2007) e895
21. Rhoades K.L., Golub S.H., and Economou J.S. The regulation of the human tumor necrosis factor alpha promoter region in macrophage, T cell, and B cell lines. J. Biol. Chem. 267 (1992) 22102-22107
22. Schmitt I., Evert B.O., Khazneh H., Klockgether T., and Wüllner U. The human MJD gene: genomic structure and functional characterization of the promoter region. Gene 18 314 (2003) 81-88
23. Sriram K., Matheson J., Benkovic S.A., Miller D.B., Luster M.I., and O J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16 (2002) 1474-1476
24. Sriram K., Matheson J., Benkovic S.A., Miller D.B., Luster M.I., and O J.P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J. 20 (2006) 670-682
25. Suzuki M.M., and Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nature Reviews Genetics 9 (2008) 465-476
26. Takashiba S., Shapira L., Amar S., and Van Dyke T.E. Cloning and characterization of human TNF-alpha promoter region. Gene 15 (1993) 307-308
27. Wahner A.D., Bronstein J.M., Bordelon Y.M., and Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69 19 (2007) 1836-1842
28. Watson W.H., Zhao Y., and Chawla R.K. S-adenosylmethionine attenuates the lipopolysaccharide-induced expression of the gene for tumor necrosis factor alpha. Biochem. J. 15 (1999) 21-25
29. Veal N., Hsieh C., Xiong S., Mato J.M., Lu S., and Tsukamoto H. Inhibition of lipopolysaccharide-stimulated TNF-alpha promoter activity by S-adenosylmethionine and 5′-methylthioadenosine. Am. J. Physiol. Gastrointest. Liver. Physiol. 287 (2004) 352-362